CPG News Alerts

• FDA Reminds the Public about the Potential for Life-Threatening Harm from Accidental Exposure to Fentanyl Transdermal Systems (“Patches”)



• Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume



• Read the MedWatch safety alert, including a link to the FDA Safety Communication.



• The MedWatch March 2012 Safety Labeling Changes:
  

  The following drugs had modifications to the BOXED WARNINGS, CONTRAINDICATIONS and WARNINGS sections:

  Atacand HCT (candesartan cilextetil/hydrochlorothiazide)
  Benicar (olmesartan medoxomil)
  Sporanox (itraconazole)
  Twynsta (telmisartan/amlodipine)
  Zestoretic (lisinopril/hydrochlorothiazide)
  Zestril (lisinopril)
  Benlysta (belimumab)
  Celexa (citalopram hydrobromide)
  Enablex (darifenacin)
  Incivek (telaprevir)
  Janumet (sitagliptin and metformin fixed-dose combination)
  Januvia (sitagliptin)
  Kombiglyze XR (saxagliptin/metformin hydrochloride extended-release)
  Lidocaine in 5% Dextrose Injection
  Magnevist (brand of gadopentetate dimeglumine)
  Revlimid (lenalidomide)
  Reyataz (atazanavir sulfate)
  Treximet (sumatriptan and naproxen sodium)
  Votrient (pazopanib)
  Zometa (zoledronic acid)
  Zmax (azithromycin extended release)

• Drug that treats symptoms of schizophrenia available for first time as a generic



• FDA 2012 Medwatch Safety Alerts



• Warning: Potential for lethal insulin overdose based on incorrect blood glucose readings



• FDA MedWatch - Celexa (citalopram hydrobromide) - Drug Safety Communication: Revised Recommendations, Potential Risk of Abnormal Heart Rhythms